Immune Gene Regulation in Human Trophoblast Cells

人类滋养层细胞的免疫基因调控

基本信息

  • 批准号:
    8304279
  • 负责人:
  • 金额:
    $ 30.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-10 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Successful pregnancy requires that the antigenically disparate fetus avoid attack by the mother's immune system. Placental trophoblast cells (TBCs) are the only blastocyst-derived cells in direct contact with maternal blood, and they play essential roles in modulating maternal immune responses to the conceptus. Interferon-3 (IFN-3) is a pro-inflammatory cytokine that plays critical roles in diverse cellular processes, including induction of apoptosis, inhibition of cell proliferation and initiation of adaptive immune responses. Importantly, IFN-3 is present in the uterus during normal pregnancy. Human TBCs from all gestational ages examined are resistant to both IFN-3-mediated apoptosis, and activation of polymorphic MHC antigen expression. This suggests that human TBCs have evolved mechanisms to evade the harmful effects of IFN-3. Responses to IFN-3 are mediated by activation of transcription through the JAK-STAT-1 pathway. Importantly, multiple pathogens evade host immune responses by disrupting the JAK-STAT pathway in response to IFN-3. The magnitude and duration of cellular responses to IFN-3 are dictated by the equilibrium between the activities of the positively acting JAKs and STATs, versus negatively acting protein tyrosine phosphatases (PTPs) and suppressors of cytokine signaling (SOCS). The PTPs that regulate IFN-3 signaling are constitutively active, but are transiently inactivated following exposure of cells to IFN-3. Inactivation of the PTPs results in maximal activation of the JAKs and propagation of the cytokine signal. We previously demonstrated that IFN-3 responses are inhibited in human primary term TBCs and TBC-derived choriocarcinoma (CC) cells by PTP-mediated repression of the JAKs. Our kinetic studies demonstrate that JAKs are inhibited in TBCs even at early time points of IFN-3 treatment. These results suggest that the PTPs are not inactivated in TBCs exposed to IFN-3. We also recently demonstrated that SOCS-1 and SOCS-3 are constitutively expressed in TBCs. Thus, in Specific Aim I, we will investigate 1) whether PTPs are differentially regulated in IFN-3-treated TBCs versus other cell types, and 2) the roles of SOCS-1 and SOCS-3 in regulating IFN-3 responses in TBCs. Our collective studies suggest that inhibition of the JAKs is the primary mechanism by which TBCs suppress IFN-3 responses, but they do not address the consequences of aberrant JAK or STAT-1 activation on trophoblastic responses to IFN-3. Recent studies identified an association between unexplained pregnancy loss and a constitutively active (CA) mutant of JAK-2. Moreover, STAT-1 plays an essential role in immunosurveillance of tumors. Thus, in Specific Aim II, we will investigate the effects of CA mutants of the JAKs and STAT-1 on TBC IFN-3 responses. It is currently unclear whether inhibition of IFN-3 signaling in TBCs occurs throughout gestation, or is restricted to specific trimesters of pregnancy. Thus, in Specific Aim III we will examine IFN-3 responses in 1st, 2nd and 3rd trimester TBCs. Our studies will provide insights into how the conceptus evades deleterious responses to IFN-3, and how aberrant IFN-3 signaling in TBCs may lead to complications of pregnancy. PUBLIC HEALTH RELEVANCE: Recent studies suggest that pregnancy is a state of controlled inflammation, and that alterations in placental levels of IFN-3 play a critical role in placental pathology versus reproductive success. Our proposed studies will shed light on how TBCs compensate for the presence of pro-inflammatory IFN-3 in the uterus during normal pregnancy and following infection by providing a comprehensive analysis of the molecular mechanism(s) by which TBCs regulate responses to IFN-3. Thus, our studies will provide insights into how the conceptus evades potentially deleterious responses to IFN-3, and how aberrant cytokine signaling in TBCs may lead to pregnancy complications. This work also has important implications for tumor immunity, for loss of responsiveness to IFN-3 by tumor cells plays an essential role in tumor immunoevasion.
描述(申请人提供):成功的怀孕需要抗原性不同的胎儿避免母亲的免疫系统攻击。胎盘滋养层细胞(TbCs)是唯一与母体血液直接接触的胚泡来源细胞,在调节母体对妊娠的免疫反应中发挥着重要作用。干扰素-3(IFN-3)是一种促炎细胞因子,在多种细胞过程中发挥重要作用,包括诱导细胞凋亡、抑制细胞增殖和启动适应性免疫反应。重要的是,在正常妊娠期间,干扰素-3存在于子宫中。来自所有胎龄的人脐带血对干扰素-3介导的细胞凋亡和多态MHC抗原表达的激活都具有抵抗力。这表明人类的脐带血细胞已经进化出逃避干扰素-3的有害影响的机制。对干扰素-3的反应是通过JAK-STAT-1途径激活转录介导的。重要的是,多种病原体通过扰乱JAK-STAT通路对干扰素-3的反应来逃避宿主免疫反应。细胞对干扰素-3反应的幅度和持续时间由正向作用的JAK和STATs的活性与负向作用的蛋白酪氨酸磷酸酶(PTPs)和细胞因子信号转导抑制物(SOCs)之间的平衡决定。调节干扰素-3信号的PTP在结构上是活跃的,但在细胞暴露于干扰素-3后会暂时失活。PTPs的失活导致JAK的最大激活和细胞因子信号的传播。我们先前证明,通过PTP介导的JAK的抑制,人的初代足月胎肾细胞和TBC来源的绒毛膜癌(CC)细胞中的干扰素-3反应被抑制。我们的动力学研究表明,即使在干扰素-3治疗的早期时间点,JAK在TBCs中也受到抑制。这些结果表明,在暴露于干扰素-3的TBCs中,PTP没有被灭活。我们最近还证明了SOCS-1和SOCS-3在TBCs中有结构性表达。因此,在特定的目标I中,我们将研究1)在干扰素-3处理的TBCs中,PTPs是否与其他类型的细胞有不同的调控,以及2)SOCS-1和SOCS-3在调控TBCs中的干扰素-3反应中所起的作用。我们的集体研究表明,抑制JAK是TBCs抑制干扰素-3反应的主要机制,但它们没有解决JAK或STAT-1异常激活对滋养细胞对干扰素-3反应的后果。最近的研究发现,原因不明的妊娠丢失与JAK-2的结构性活性(CA)突变之间存在关联。此外,STAT-1在肿瘤的免疫监测中起着至关重要的作用。因此,在特定的目标II中,我们将研究JAK和STAT-1的CA突变对TBC干扰素-3应答的影响。目前尚不清楚脐带血中干扰素-3信号的抑制是发生在整个妊娠过程中,还是仅限于妊娠的特定三个月。因此,在特定目标III中,我们将检查妊娠1、2和3个月的脐带血中的干扰素-3反应。我们的研究将为胎儿如何逃避对干扰素-3的有害反应,以及脐带血中异常的干扰素-3信号如何导致妊娠并发症提供见解。公共卫生相关性:最近的研究表明,怀孕是一种受控的炎症状态,胎盘中干扰素-3水平的变化在胎盘病理与生殖成功之间起着关键作用。我们拟议的研究将通过全面分析脐带血细胞调节干扰素-3反应的分子机制,阐明脐带血细胞如何补偿正常妊娠期间和感染后子宫中促炎症干扰素-3的存在(S)。因此,我们的研究将为了解胚胎如何逃避对干扰素-3的潜在有害反应,以及脐带血细胞中异常的细胞因子信号如何导致妊娠并发症提供见解。这项工作对肿瘤免疫也有重要意义,因为肿瘤细胞对干扰素-3的反应性丧失在肿瘤免疫逃避中起着至关重要的作用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Optimized logic rules reveal interferon-γ-induced modes regulated by histone deacetylases and protein tyrosine phosphatases.
优化的逻辑规则揭示了由组蛋白脱乙酰酶和蛋白酪氨酸磷酸酶调节的干扰素-γ诱导模式。
  • DOI:
    10.1111/imm.12707
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    VanTwisk,Daniel;Murphy,ShawnP;Thakar,Juilee
  • 通讯作者:
    Thakar,Juilee
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHAWN P MURPHY其他文献

SHAWN P MURPHY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHAWN P MURPHY', 18)}}的其他基金

Immune Gene Regulation in Human Trophoblast Cells
人类滋养层细胞的免疫基因调控
  • 批准号:
    8100195
  • 财政年份:
    2009
  • 资助金额:
    $ 30.47万
  • 项目类别:
Immune Gene Regulation in Human Trophoblast Cells
人类滋养层细胞的免疫基因调控
  • 批准号:
    7928941
  • 财政年份:
    2009
  • 资助金额:
    $ 30.47万
  • 项目类别:
REGULATION OF MHC CLASS II EXPRESSION IN TROPHOBLAST
滋养细胞中 MHC II 类表达的调节
  • 批准号:
    6388069
  • 财政年份:
    1999
  • 资助金额:
    $ 30.47万
  • 项目类别:
REGULATION OF MHC CLASS II EXPRESSION IN TROPHOBLAST
滋养细胞中 MHC II 类表达的调节
  • 批准号:
    2827357
  • 财政年份:
    1999
  • 资助金额:
    $ 30.47万
  • 项目类别:
REGULATION OF MHC CLASS II EXPRESSION IN TROPHOBLAST
滋养细胞中 MHC II 类表达的调节
  • 批准号:
    6181864
  • 财政年份:
    1999
  • 资助金额:
    $ 30.47万
  • 项目类别:
EXAMINATION OF INTERACTIONS BETWEEN HUMAN HSP70 AND P53
人类 HSP70 和 P53 之间相互作用的检查
  • 批准号:
    3046033
  • 财政年份:
    1992
  • 资助金额:
    $ 30.47万
  • 项目类别:
EXAMINATION OF INTERACTIONS BETWEEN HUMAN HSP70 AND P53
人类 HSP70 和 P53 之间相互作用的检查
  • 批准号:
    3046031
  • 财政年份:
    1991
  • 资助金额:
    $ 30.47万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 30.47万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 30.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 30.47万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 30.47万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了